Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.

Purpose: Esaxerenone is a novel, oral, nonsteroidal treatment for hypertension. Physiologically based pharmacokinetic (PBPK) modelling was performed to predict the drug–drug interaction (DDI) effect of cytochrome P450 (CYP)3A modulators on esaxerenone pharmacokinetics in healthy subjects and subject...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 78; no. 1; pp. 65 - 74
Main Authors:	Watanabe, Akiko, Ishizuka, Tomoko, Yamada, Makiko, Igawa, Yoshiyuki, Shimizu, Takako, Ishizuka, Hitoshi
Format:	research tables/charts Journal Article
Published:	Springer Nature Jan2022
Online Access:	View this record in EBSCOhost